- Home
- Publications
- Publication Search
- Publication Details
Title
Combination therapy for obesity
Authors
Keywords
-
Journal
JOURNAL OF PSYCHOPHARMACOLOGY
Volume 31, Issue 11, Pages 1503-1508
Publisher
SAGE Publications
Online
2017-11-14
DOI
10.1177/0269881117737401
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Bench to bedside in appetite research: Lost in translation?
- (2017) R.J. Rodgers NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
- Drug-induced obesity and its metabolic consequences: a review with a focus on mechanisms and possible therapeutic options
- (2017) A. A. Verhaegen et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Unimolecular Polypharmacy for Treatment of Diabetes and Obesity
- (2016) Matthias H. Tschöp et al. Cell Metabolism
- Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release
- (2016) Bruno Halpern et al. Expert Opinion On Drug Safety
- Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors
- (2016) Steven E. Nissen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Management of obesity
- (2016) George A Bray et al. LANCET
- Method-of-use study of naltrexone sustained release (SR)/bupropion SR on body weight in individuals with obesity
- (2016) Amy Halseth et al. Obesity
- Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial
- (2016) Juan P Frías et al. Lancet Diabetes & Endocrinology
- Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition
- (2015) S. P. Rajeev et al. DIABETES OBESITY & METABOLISM
- Naltrexone Extended-Release Plus Bupropion Extended-Release for Treatment of Obesity
- (2015) Susan Z. Yanovski et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Weight-Loss Therapy in Type 2 Diabetes: Effects of Phentermine and Topiramate Extended Release
- (2014) W. Timothy Garvey et al. DIABETES CARE
- Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
- (2014) Ele Ferrannini et al. JOURNAL OF CLINICAL INVESTIGATION
- A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
- (2014) Brian Finan et al. NATURE MEDICINE
- Naltrexone/bupropion for obesity: An investigational combination pharmacotherapy for weight loss
- (2014) Sonja K. Billes et al. PHARMACOLOGICAL RESEARCH
- Prevention of Type 2 Diabetes in Subjects With Prediabetes and Metabolic Syndrome Treated With Phentermine and Topiramate Extended Release
- (2013) W. Timothy Garvey et al. DIABETES CARE
- Effects of Naltrexone Sustained- Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes
- (2013) P. Hollander et al. DIABETES CARE
- Addiction potential of phentermine prescribed during long-term treatment of obesity
- (2013) E J Hendricks et al. INTERNATIONAL JOURNAL OF OBESITY
- Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery
- (2013) L. Sjöström JOURNAL OF INTERNAL MEDICINE
- Canagliflozin: Effects in overweight and obese subjects without diabetes mellitus
- (2013) Harold E. Bays et al. Obesity
- A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II)
- (2013) Caroline M. Apovian et al. Obesity
- Acute behavioural effects of bupropion and naltrexone, alone and in combination, in non-deprived male rats presented with palatable mash
- (2013) F. L. Wright et al. PSYCHOPHARMACOLOGY
- Anti-obesity drugs: past, present and future
- (2012) R. J. Rodgers et al. Disease Models & Mechanisms
- Weight Loss Induced by Chronic Dapagliflozin Treatment Is Attenuated by Compensatory Hyperphagia in Diet-Induced Obese (DIO) Rats
- (2012) James J. Devenny et al. Obesity
- Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study
- (2011) W Timothy Garvey et al. AMERICAN JOURNAL OF CLINICAL NUTRITION
- Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP)
- (2011) David B. Allison et al. Obesity
- Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- (2010) Frank L Greenway et al. LANCET
- Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
- (2010) W. Philip T. James et al. NEW ENGLAND JOURNAL OF MEDICINE
- Weight Loss With Naltrexone SR/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification: The COR-BMOD Trial
- (2010) Thomas A. Wadden et al. Obesity
- CB1 antagonists for obesity—what lessons have we learned from rimonabant?
- (2009) Vincenzo Di Marzo et al. Nature Reviews Endocrinology
- Rational Design of a Combination Medication for the Treatment of Obesity
- (2008) Frank L. Greenway et al. Obesity
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now